Collectionner le produit
Détails du produit
- ItemsSize 2mgSize 10mg (5mg × 2)Particle size2 μm2 μmPhysical appearancePowder mixturePowder mixtureBinding Capacity>200 pmol (30 μg) antibody/mg beads>200 pmol (30 μg) antibody/mg beadsFormulationPBS, pH7.4, with 10% TrehalosePBS, pH7.4, with 10% TrehaloseReconstitution2 mL sterile deionized water (1 mg beads/mL)5 mL sterile deionized water (1 mg beads/mL)
Product Description
The Human EGFRvIII-coupled Magnetic Beads is produced by coupling biotinylated EGFRvIII protein to streptavidin-conjugated magnetic beads. Because Streptavidin (SA) has an extraordinarily high affinity for biotin with a dissociation constant (Kd) on the order of 10-14 mol/L, the biotinylated protein can bind to the SA beads irreversibly. The pre-coupled beads are ready to use for capturing anti-EGFRvIII antibody from your sample with high specificity.
Application
This product is intended for immunocapture, biopanning. This is a non-sterile product.
* The Isotype control (Cat. No. SMB-B01) is sold separately.
Reconstitution
See Certificate of Analysis (CoA) for detailed instruction.
Storage
Upon receipt, please store the beads at -20°C. The shelf life is 6 months at -20 °C.
Please avoid more than 3 freeze-thaw cycles once reconstitution, immediate use after reconstitution is highly recommended.
Assay Principles
Antibody Purification:
1. Resuspend the lyophilized beads by adding the buffer of choice.
2. Add analyte to the suspension, mix and incubate to enable specific binding of the beads and the target protein.
3. Magnetize beads, remove supernatant, and wash unbound protein fractions to capture target protein-bound beads.
4. Wash, magnetize the beads and collect purified target protein for use in downstream applications.The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
Typical Data
Immobilized 44 μg EGFRvIII protein/1 mg beads can bind Anti-EGFR Antibody (Cetuximab) with an EC50 of 0.7172 μg/mL.
Protocol
Immobilized 44 μg EGFRvIII protein/1mg beads can bind Anti-EGFRvIII Antibody with an EC50 of 0.8856 μg/mL (Routinely tested).
Protocol
Avis des utilisateurs Publier un commentaire
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Epidermal growth factor receptor variant III
- Catégorie：
- Nombre de médicaments répertoriés：
0 Détails
- Nombre de médicaments cliniques：
14 Détails
- Étape de développement la plus élevée：
Phase 2 Clinical
Contact Us
Drug Candidate Licensing
